cis-Dichlorodiammineplatinum(II) and hexamethylmelamine in the treatment of non-oat cell lung cancer

A pilot study of the Southeastern Cancer Study Group

S. Krauss, K. Tornyos, P. DeSimone, S. Lowenbraun, J. McKeown, Alan Solomon, T. Sonoda

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Fifty-one patients with metastatic non-oat cell carcinoma of the lung were treated with a combination of cis-dichlorodiammineplatinum (II) and hexamethylmelamine. The overall response rate (all cell types) was 16%. Four of 20 patients with adenocarcinoma had a partial response and an additional five patients classified as having stable disease had tumor regression <50%. The median survival of responders and of those with stable disease (all types) was 8 and 7 months respectively, significantly longer than the median survival of patients who progressed (median survival, 2 months [P<0.05]). The major dose-limiting toxicity was nausea and vomiting in over half of the patients; hematologic toxicity and peripheral neuropathy were the other adverse effects of the combination.

Original languageEnglish (US)
Pages (from-to)391-393
Number of pages3
JournalCancer Treatment Reports
Volume63
Issue number3
StatePublished - Dec 1 1979

Fingerprint

Altretamine
Cisplatin
Lung Neoplasms
Neoplasms
Survival
Therapeutics
Peripheral Nervous System Diseases
Nausea
Vomiting
Adenocarcinoma
Carcinoma
Lung

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

cis-Dichlorodiammineplatinum(II) and hexamethylmelamine in the treatment of non-oat cell lung cancer : A pilot study of the Southeastern Cancer Study Group. / Krauss, S.; Tornyos, K.; DeSimone, P.; Lowenbraun, S.; McKeown, J.; Solomon, Alan; Sonoda, T.

In: Cancer Treatment Reports, Vol. 63, No. 3, 01.12.1979, p. 391-393.

Research output: Contribution to journalArticle

@article{add610d2a4004f4da9b33b2cd1d9b801,
title = "cis-Dichlorodiammineplatinum(II) and hexamethylmelamine in the treatment of non-oat cell lung cancer: A pilot study of the Southeastern Cancer Study Group",
abstract = "Fifty-one patients with metastatic non-oat cell carcinoma of the lung were treated with a combination of cis-dichlorodiammineplatinum (II) and hexamethylmelamine. The overall response rate (all cell types) was 16{\%}. Four of 20 patients with adenocarcinoma had a partial response and an additional five patients classified as having stable disease had tumor regression <50{\%}. The median survival of responders and of those with stable disease (all types) was 8 and 7 months respectively, significantly longer than the median survival of patients who progressed (median survival, 2 months [P<0.05]). The major dose-limiting toxicity was nausea and vomiting in over half of the patients; hematologic toxicity and peripheral neuropathy were the other adverse effects of the combination.",
author = "S. Krauss and K. Tornyos and P. DeSimone and S. Lowenbraun and J. McKeown and Alan Solomon and T. Sonoda",
year = "1979",
month = "12",
day = "1",
language = "English (US)",
volume = "63",
pages = "391--393",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - cis-Dichlorodiammineplatinum(II) and hexamethylmelamine in the treatment of non-oat cell lung cancer

T2 - A pilot study of the Southeastern Cancer Study Group

AU - Krauss, S.

AU - Tornyos, K.

AU - DeSimone, P.

AU - Lowenbraun, S.

AU - McKeown, J.

AU - Solomon, Alan

AU - Sonoda, T.

PY - 1979/12/1

Y1 - 1979/12/1

N2 - Fifty-one patients with metastatic non-oat cell carcinoma of the lung were treated with a combination of cis-dichlorodiammineplatinum (II) and hexamethylmelamine. The overall response rate (all cell types) was 16%. Four of 20 patients with adenocarcinoma had a partial response and an additional five patients classified as having stable disease had tumor regression <50%. The median survival of responders and of those with stable disease (all types) was 8 and 7 months respectively, significantly longer than the median survival of patients who progressed (median survival, 2 months [P<0.05]). The major dose-limiting toxicity was nausea and vomiting in over half of the patients; hematologic toxicity and peripheral neuropathy were the other adverse effects of the combination.

AB - Fifty-one patients with metastatic non-oat cell carcinoma of the lung were treated with a combination of cis-dichlorodiammineplatinum (II) and hexamethylmelamine. The overall response rate (all cell types) was 16%. Four of 20 patients with adenocarcinoma had a partial response and an additional five patients classified as having stable disease had tumor regression <50%. The median survival of responders and of those with stable disease (all types) was 8 and 7 months respectively, significantly longer than the median survival of patients who progressed (median survival, 2 months [P<0.05]). The major dose-limiting toxicity was nausea and vomiting in over half of the patients; hematologic toxicity and peripheral neuropathy were the other adverse effects of the combination.

UR - http://www.scopus.com/inward/record.url?scp=0018778471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018778471&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 391

EP - 393

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

ER -